Berliner Boersenzeitung - 'Beginning of the end': patients hail new treatment for drug-resistant TB

EUR -
AED 4.28642
AFN 80.800953
ALL 97.867038
AMD 448.356022
ANG 2.088879
AOA 1070.293041
ARS 1492.768995
AUD 1.781705
AWG 2.101485
AZN 1.98322
BAM 1.951941
BBD 2.356641
BDT 141.230795
BGN 1.956885
BHD 0.439989
BIF 3373.697879
BMD 1.167168
BND 1.494858
BOB 8.094068
BRL 6.52272
BSD 1.167193
BTN 100.283604
BWP 15.573346
BYN 3.819781
BYR 22876.484491
BZD 2.344585
CAD 1.599224
CDF 3368.445444
CHF 0.930863
CLF 0.029457
CLP 1130.378758
CNY 8.365382
CNH 8.370961
COP 4680.925564
CRC 589.140351
CUC 1.167168
CUP 30.929941
CVE 110.880278
CZK 24.662843
DJF 207.429468
DKK 7.463524
DOP 70.382763
DZD 151.744621
EGP 57.719122
ERN 17.507514
ETB 159.376938
FJD 2.624084
FKP 0.8626
GBP 0.868746
GEL 3.163491
GGP 0.8626
GHS 12.141917
GIP 0.8626
GMD 83.451027
GNF 10103.002412
GTQ 8.966274
GYD 244.099521
HKD 9.162225
HNL 30.75439
HRK 7.535122
HTG 153.197138
HUF 399.935771
IDR 18987.598845
ILS 3.909819
IMP 0.8626
INR 100.340055
IQD 1528.989525
IRR 49152.342916
ISK 142.418235
JEP 0.8626
JMD 186.988732
JOD 0.827576
JPY 172.423309
KES 151.147597
KGS 102.064837
KHR 4693.181197
KMF 492.8363
KPW 1050.450605
KRW 1613.515655
KWD 0.356733
KYD 0.972685
KZT 612.47442
LAK 25134.95349
LBP 104519.85666
LKR 351.175746
LRD 234.60072
LSL 20.88822
LTL 3.446342
LVL 0.706008
LYD 6.320206
MAD 10.53427
MDL 19.772081
MGA 5170.552384
MKD 61.600511
MMK 2451.051223
MNT 4183.367519
MOP 9.437424
MRU 46.310098
MUR 53.001623
MVR 17.976039
MWK 2026.783616
MXN 21.876356
MYR 4.963377
MZN 74.652346
NAD 20.893575
NGN 1783.035451
NIO 42.940514
NOK 11.831233
NPR 160.454166
NZD 1.952193
OMR 0.448773
PAB 1.167203
PEN 4.162704
PGK 4.726154
PHP 66.142271
PKR 332.234334
PLN 4.256834
PYG 9042.124235
QAR 4.249188
RON 5.079864
RSD 117.177828
RUB 91.157316
RWF 1673.718304
SAR 4.37751
SBD 9.71032
SCR 16.471061
SDG 700.874766
SEK 11.22182
SGD 1.496455
SHP 0.91721
SLE 26.258146
SLL 24474.925093
SOS 667.023371
SRD 43.425056
STD 24158.012323
SVC 10.21281
SYP 15175.49558
SZL 20.903876
THB 37.885725
TJS 11.269218
TMT 4.096758
TND 3.381223
TOP 2.733624
TRY 46.969276
TTD 7.922406
TWD 34.269179
TZS 3025.125595
UAH 48.811085
UGX 4182.730979
USD 1.167168
UYU 47.436221
UZS 14828.863652
VES 133.271606
VND 30492.252925
VUV 139.648288
WST 3.041064
XAF 654.668367
XAG 0.030493
XAU 0.000349
XCD 3.154329
XDR 0.814138
XOF 654.780957
XPF 119.331742
YER 281.696039
ZAR 20.890776
ZMK 10505.905627
ZMW 27.078699
ZWL 375.827483
  • CMSC

    0.0900

    22.314

    +0.4%

  • CMSD

    0.0250

    22.285

    +0.11%

  • RBGPF

    0.0000

    69.04

    0%

  • SCS

    0.0400

    10.74

    +0.37%

  • RELX

    0.0300

    53

    +0.06%

  • RIO

    -0.1400

    59.33

    -0.24%

  • GSK

    0.1300

    41.45

    +0.31%

  • NGG

    0.2700

    71.48

    +0.38%

  • BP

    0.1750

    30.4

    +0.58%

  • BTI

    0.7150

    48.215

    +1.48%

  • BCC

    0.7900

    91.02

    +0.87%

  • JRI

    0.0200

    13.13

    +0.15%

  • VOD

    0.0100

    9.85

    +0.1%

  • BCE

    -0.0600

    22.445

    -0.27%

  • RYCEF

    0.1000

    12

    +0.83%

  • AZN

    -0.1200

    73.71

    -0.16%

'Beginning of the end': patients hail new treatment for drug-resistant TB
'Beginning of the end': patients hail new treatment for drug-resistant TB / Photo: Michele Spatari - AFP/File

'Beginning of the end': patients hail new treatment for drug-resistant TB

Volodymyr is celebrating a major milestone on Wednesday -- it's his final day of taking a new treatment hailed as a turning point in the fight against drug-resistant tuberculosis.

Text size:

The 25-year-old doctor in Ukraine's capital Kyiv said he had nasty neurological side effects when he was on a previous drug regimen, which takes up to two years, involves a huge number of pills and is less than 60-percent effective.

But the new treatment course took just six months, and gave him very few side effects. "It was very easy," he told AFP.

A scan on Wednesday showed he was clear of tuberculosis, and he plans to start work next week after eight months off sick.

"Now I can start life again," said Volodymyr, who did not give his last name.

Tuberculosis, once called consumption, was the world's biggest infectious killer before the arrival of Covid-19, with 1.5 million people dying from the disease each year.

Around five percent of new cases are resistant to commonly prescribed antibiotics, making them difficult to treat.

However a new drug regimen, called BPaL because it combines the antibiotics bedaquiline, pretomanid and linezolid, has been seen as a breakthrough since it was first approved by the US Food and Drug Administration in 2019.

- From 23 to five pills a day -

Research in 2020 showed that the BPaL regimen cured more than 90 percent of drug-resistant patients, however there was a high rate of side effects linked to linezolid, including nerve pain and bone marrow suppression.

But a study published in the New England Journal of Medicine on Wednesday indicated that the dosage of linezolid can be halved.

A trial involving 181 participants with drug-resistant tuberculosis was carried out in Russia, South Africa, Georgia and Moldova -- all countries with high TB rates.

It found that while 1,200 milligrams of linezolid over six months had a cure rate of 93 percent, that number only dropped to 91 percent if the dosage was halved to 600 milligrams.

The number of participants with the side of peripheral neuropathy -- which causes nerve pain -- fell from 38 to 24 percent at the lower dosage, while the rate of bone marrow suppression dropped from 22 to two percent.

The study's lead author, Francesca Conradie of South Africa's University of the Witwatersrand, said she was "overwhelmed with how successful this regimen was".

"This is the beginning of the end of drug-resistant TB," she told AFP.

"The quicker you treat someone's TB, the less infectious they are -- it's like Covid in many ways."

It is also far easier for patients to take BPaL, she added, saying previous courses could involve 23 pills a day -- and up to 14,000 total pills over the maximum two-year course.

BPaL involves five pills a day -- and fewer than 750 over six months.

- Could TB surpass Covid? -

Nataliia Lytvynenko, who has overseen BPaL treatments in Ukraine, said the more manageable amount of pills meant it was easier for patients to continue treatment after being displaced by the war in her country.

The World Health Organization indicated earlier this year that it would soon update its guidelines to recommend most patients with drug-resistant TB use BPaL with 600 milligrams of linezolid.

Two experts not involved in Wednesday's study said the research and the WHO guidance were "major advances".

The BPaL treatment "is one of the defining achievements of the tuberculosis research community in this century," Guy Thwaites of Britain's Oxford University and Nguyen Viet Nhung of Vietnam's National Tuberculosis Control Programme wrote in an editorial in the New England Journal of Medicine.

The advances come amid warnings that the pandemic has stalled progress against tuberculosis.

"I very much worry that TB will -- whether it's this year or next -- again become the largest single killer of any infectious disease in the world," said Mel Spigelman, the president of the non-profit TB Alliance which funded the research.

Volodymyr meanwhile said he hoped that progress would continue so the treatment timeline gets even shorter.

"Maybe it will be two months -- or even one," he said with a smile.

(U.Gruber--BBZ)